William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline

Company Overview - Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a clinical-stage biotechnology company focused on developing therapies for heart disease, with lead product candidates including TN-401, TN-201, and TN-301 [5]. Investment Outlook - Andy Hsieh of William Blair maintained a Buy rating on Tenaya Therapeutics, citing a positive outlook due to the company's advancing pipeline and improving regulatory clarity [1]. - Expected alignment with regulators on pivotal trial designs for TN-201 and TN-401 could serve as a major de-risking event, providing clearer approval pathways and better visibility on potential value drivers and timelines [1]. Clinical Developments - Momentum into 2026 is supported by resumed enrollment in the MyPEAK-1 study for TN-201 and positive DSMB safety feedback on TN-401, which allows for dose expansion [3]. - Early data from TN-301 is significant as it expands the platform beyond gene therapy, potentially adding a third growth pillar, with sufficient capital available to execute current plans [3]. Financial Performance - For the fourth quarter, Tenaya Therapeutics reported a GAAP EPS of -$0.12, aligning with expectations [4]. - As of December 31, 2025, the company held $100.5 million in cash, cash equivalents, and investments in marketable securities, an increase from $61.4 million at the end of December 2024, reflecting net proceeds of $55.8 million raised through a public offering [4].